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 ABSTRACT 
Diagnosis of glomerulopathy requires correlation between: (a) clinicopathological syndromes, (b) kidney histology for the abnormalities which 
are useful for the severity of disease, stage of activity and extent of chronicity.  Subsequently, management dictates the choice of effective 
medications to avoid renal loss and long-term side effects.  In this review article; we provide our practical experience with drug-therapy in 
common idiopathic and secondary glomerular diseases.  
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INTRODUCTION 
Glomerulopthy (G) is an injury to the glomerulus.  The latter 
is the first segment of the nephron which is responsible for 
filtration of blood received from the afferent arteriole and 
existing via the efferent one.  The glomerulus is formed by 
the branching of the afferent arteriole which loses its 
muscular wall and left only with a glomerular basement 
membrane (BM) and an inner lining of endothelial cells.  The 
latter arrangement is to provide an unhindered filtration 
process (Fig.1).  The filtered fluid is collected in the first part 
of the urinary tubules which is the bowman space formed by 
an inner visceral and an out parietal layer of the bowman 
capsule. 
MANIFESTATIONS OF G 
G is a common cause of renal disease with an annual 
incidence rate 34.5 per 100,000 populations (PTP) [1].  In 
the latter study 21.1 PTP were non-diabetic G, of whom 
secondary lesions viz. lupus nephritis and vasculitis shared 
4.8 PTP.  G manifests as proteinuria caused by altered 
permeability of the BM, hematuria if BM ruptures, oliguria if 
reduced filtration of fluids leading to fluid overload, oedema 
and hypertension and lastly azotemia if impaired filtration of 
nitrogenous end-products of catabolism.  The prognosis of G 
depends on nature of disease and its severity. 
 
 
 
 
Figure 1: Showing ultrastructural features of normal 
glomerulus 
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DIAGNOSIS OF G 
It requires recognition of: (a) clinicopathological syndromes, 
(b) kidney histology for the abnormalities which are useful 
for the severity of disease, stage of activity and extent of 
chronicity.  The clinicopathological abnormalities includes; 
clinical manifestations, routine laboratory tests and 
serological markers of disease.  The latter serum tests 
include; complements (C3 & C4), ANA, anti-dsDNA, ANCA, 
anti-GBM antibodies, IgA level, SPEP, HBsAg and hepatitis C 
antibodies.  Finally; the correlation between both is essential 
for final diagnosis.   Kidney biopsy establishes the 
histological type and guides selection of its specific therapy 
of since some G are steroid-refractory.  The next step is to 
assess if the histological diagnosis fits with the 
clinicopathological syndromes i.e. clinicopathological 
correlation since: (a) some histological diagnosis are 
secondary to systemic diseases, (b) superimposed G have 
been reported.  An example of the latter is a case of acute 
nephrotic syndrome (NS) in a diabetic glomerulosclerosis 
(DGS) or an IgA histological features; can’t rule out minimal 
change disease (MCD) superimposed on those G.  Diagnosis 
of the latter may prove to be difficult even with the aid of 
electron microscopy to evaluate ultrastructual deposits and 
BM changes and an empiric trial of short-course of 
Prednisone may confirm diagnosis.  
CLINICOPATHOLOGICAL SYNDROMES 
Those with their corresponding histological lesions are 
summarized in Table 1.  They include 4 clinical syndromes; 
(a) NS characterized by history of oedema and proteinuria > 
3.5 g/day, (b) advanced NS (with renal impairment) i.e. all 
diseases in the first group except pure MCD, (c) acute renal 
failure with hematuria and proteinuria which includes 
patients with proliferative and crescentic glomerular lesions, 
(d) asymptomatic hematuria with/without hematuria and 
renal impairment accidently disclosed during routine work 
up.   
MECHANISMS OF G 
1- MCD: The initial event starts by activation of T-
lymphocyte leading to stimulation of B-lymphocyte to 
liberate a permeability factor [2].  The latter abolishes 
the negative charge on glomerular BM.  Serum albumin 
is a negatively-charged small molecule that can easily 
pass through the fenestra of the BM yet is normally 
repelled by the negative charge on BM.  Interestingly, 
such phenomenon prevents the attachment of the 
visceral layer of bowman capsule on the epithelial 
(outer) side of BM leading to a foot-process structure.  
Once the negative charge is lost; albumin can passes 
freely through the fenestra of BM and the visceral cells 
spread on the BM losing the foot-processes shape.  
Since the defect is loss of negative charge of BM rather 
than an inflammatory process; MCD is not associated 
with glomerulosclerosis.  The initiating factor from T-
lymphocyte is interleukins which can be blocked by 
Calcineurin inhibitors (CNI) and activated mature B-
lymphocyte can be targeted with Rituximab [3, 4].   
2- Certain immune complexes (IC) are bland and do not 
generate inflammatory response such as idiopathic 
membranous G (MG).  Hence; treatment is only if 
severe NS and evidence of glomerulosclerosis [5].  
Since deposits; with Rituximab therapy, improvement 
in MG may need 2 months compared to only few days 
in MCD since the latter is an electrical defect [6]. 
3- Slow deposition of IC may be associated with mild 
inflammation leading to mild G with limited 
glomerulosclerosis such as IgA nephropathy [7].  
However, in genetically predisposed patients, high-
load of such IC leads to abnormal mesangial cells 
reaction with subsequent progressive 
glomerulosclerosis and kidney loss.  The G is the most 
common G in Far East and South East Asia and Europe 
and accounts for 25% of G.  Since not a florid 
inflammation; such phenotype rarely benefits from 
chronic immunosuppression [8]. 
4- Idiopathic focal and segmental glomerulosclerosis 
(FSGS) is induced by a mixture of another form of 
permeability factor and IC disease [9].  The IC is IgM 
and starts segmentally leading to progressive sclerosis 
and subsequent hyperfiltration, hypertension and 
progressive G.  If treated early; its acute NS can 
improve.  However, it needs long-term maintenance 
therapy and if untreated; 50% can progress to end-
stage kidney disease within 5 years [10]. 
5- Inflammatory lesions are initiated by antigens.  Some 
are short-lived such as post-streptococcal 
glomerulonephritis or clear after treatment of 
infections such as post-infectious and 
membranoproliferative ones [11, 12].  However, high-
load deposits as in lupus nephritis can initiate severe 
inflammatory response with endothelial cell 
proliferation, necrosis and rupture of BM leading to 
crescent formation by activation of podocytes of the 
visceral layer of bowman capsule [13].  Hence, an 
according to genetic predisposition, lupus nephritis 
can present as membranous G, proliferative G and IC 
crescentic G.  The disease needs aggressive 
immunosuppressive therapy to stop the active process 
(induction phase) followed by an effective and safe 
long-term maintenance immunosuppressive treatment 
to prevent its relapse [14].  Vasculitis is another severe 
systemic vascular autoimmune disease [15].  
Involvement of medium-sized vessels, in polyarteritis 
nodosa, leads to kidney infarctions and stripped 
fibrotic renal loss.  Small-vessel disease can lead to 
glomerular BM damage with necrotizing G and/or 
crescentic one if vessel ruptures leading to podocyte 
disease.  The latter presentation is common in 
Wegner’s granulomatosis, microscopic polangiitis and 
anti-glomerular BM disease. 
TREATMENT OF COMMON GLOMERULAR 
DISEASES: 
Management of common glomerulopathy is summarized in 
table 2.  Certain issues should be respected: 
1- Nearly 90% of NS in children is due to steroid-
responsive MCD.  In adult population; the prevalence 
falls to 20% with nearly 40% are due to MG which is 
steroid-refractory G [16].  Hence, kidney biopsy; 
should be done in any adult with NS except for typical 
DGS.   
2- The prevalence of DGS is 50% in type I DM and 20% in 
type II DM.  The classic presentation of DGS is with 4 
signs; slowly progressive NS, > 5 years after type II or > 
10 years in type I, normal-sized kidneys and 
proliferative retinopathy.  The latter findings should be 
associated with negative clinical, laboratory and 
serological markers of autoimmune diseases.  Since 
type II DM is common and DGS is prevalent in 20% of 
those diabetics; kidney biopsy is rarely done if 
presentation is typical [17].  However, unexplained 
acute renal and sudden NS in an already accepted DGS 
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3- Clinically indicates kidney biopsy to rule out 
superimposed lesions or an initial misdiagnosis [18]. 
4- In rapidly progressive G; aggressive 
immunosuppressive induction therapy should be 
initiated till the final histopathological diagnosis is 
available. 
5- Overall, immunosuppressive drugs should be 
efficacious and with minimal long-term side effects.  
Rituximab, if financially accessible, is preferred to long-
term Corticosteroids, Alkylating agents and even CNI 
[6].  The latter drugs are efficacious alone or in 
combination with others in some cases of FSGS.  
However, caution should be exercised on long-term 
treatment and with doses > 3 mg/kg to avoid 
interstitial fibrosis [19].  
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Table 1: Clinicopathological syndromes of common glomerulopathies 
 
 
Nephrotic 
 
Advanced nephrotic 
  
Nephritic 
  
Asymptomatic hematuria 
 
  (oedema + proteinuria > 3.5 g/day)         (ARF+Proteiuria)     (+ proteinuria)   
           
     
Proliferative 
 
Crescentic 
  
   
All NS except  1- Post-infectious/strept 1- Anti-GBM disease 1- IgA nephropathy 
1- Minimal change disease 
 
pure MCD 
 
2- Lupus nephritis 2- Immuncomplex mediated 2- Thin membrane disease 
 
a- Primary 
     
3- Pauci-immune deposits/vasculitis 3- Alport's syndrome 
 
b- Secondary: Hodgkin, Leukemia 
        
2- Membranous glomerulopathy 
         
 
a- Primary 
         
 
b- Solid cancers, drugs (d-PNC, gold), SLE, infections 
      
3- Focal segmental glomerulosclerosis 
        
 
a- Primary 
         
 
b- Secondary: genetic, HIV, hyperfiltration, obesity, drugs 
     
4- Membranoproliferative:  
         
 
a- Rarely idiopathic (causes: infections including: Hepatitis C + Cryoglobulinemia) 
   
 
b- C3 glomerulopathy 
         
5- Fibrillary/immunotactoid 
         
6- Nodular glomerulosclerosis: 
         
 
Diabetic GS 
         
 
Amyloidosis/Light chain 
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Table 2. Immunosuppressive treatment of common primary glomerulopathy 
Glomerulopathy     Treatment 
      
 
A- Minimal change disease: 
  
  
I- Steroid-responsive: 
 
Prednisone for 3 months* 
   
1- No further relapse (10%) 
 
None 
   
2- Infrequent relapser (30%): 
 
Repeat Prednisone course* 
   
3- Frequent relapser/steroid-dependent (50%): C-IH + MMP for 1 year or yearly Rituximab (1-4 years) 
  
II- Steroid-resistant (10%): 
 
Rx as FSGS 
 
B- Membranous glomerulopathy: 
  
   
1- Induction: 
 
C-IH + MMP 
   
2- Maintenance:  
 
yearly Rituximab for 4-5 years 
 
C- Focal segmental glomerulosclerosis: 
  
   
1- Induction:  
 
C-IH + MMP 
   
2- Maintenance:  
 
Yearly Rituximab + C-IH + MMP 
 
D- MPGN: 
   
   
1- Treat underlying infection: 
 
1-  If hepatitis + Cryglobulinemia: Solvady + yearly Rituximab (if NS) 
   
2- C3-glomerulopathy: 
 
2- No specific immunosuppressive Rx 
 
E- Diabetic glomerulosclerosis: 
 
Control hyperglycemia & ACEI/ARB (control hypertension and 
     
hyperfiltration): slows the disease 
 
F- Amyloidosis/Light chain: 
 
Treat the cause & if MM or Light chain: chemotherapy 
 
G- Lupus nephritis (stage3 & 4 & NS with membranous): 
 
   
1- Induction phase (3 months): 
 
Combination of 3 agents: Steroid ** + MMP + IV cyclophosphamide 
   
2- Maintenance phase: 
 
Rituximab yearly infusions or Prednisone 5 mg/day + MMP 
 
H- Vasculitis/Crescentic glomerulopathy: 
  
   
1- Induction phase (3 months): 
 
Combination of 3 agents: Steroid ** + MMP + IV cyclophosphamide 
   
2- Maintenance phase (2 years): 
 
Rituximab yearly infusions or Prednisone 5 mg/day + MMP 
   
N.B.: if anti-GBM vasculitis: plasma exchange should be added 
   
 
    
Abbreviations & dosage of medications: 
  * Prednisone 2 mg/kg/day (< 60 mg/m2) for 4 weeks then taper down gradually till discontinuation by 3rd month 
** 1 g of Solumedrol IV daily for 3 days followed by Prednisone 2 mg/kg/day (not > 60 mg/day) foe 4 weeks then to be tapered down till 5 mg/day 
MMP: Mycophenolate mofetil; dose: 600 mg/m2 orally 2 times a day up to a maximum of 2 grams per day   
Cyclophosphamide 750 mg/m2 IV monthly infusions in 200 ml of normal saline over 2 hours 
C-IH: Calcineurin inhibitors: 
  
 
A- Tacrolimus (Prograf): 0.1 mg/kg/day up to 2 mg twice daily 
 
 
B- Cyclosporine A (Neoral): 5 mg/kg/day up to 100 mg twice daily 
 
